70 - Labeling, Risk Management, and REMS (S5E10)

OK, so today we're going deep on something that's
super important, but maybe not something everyone
thinks about right away when it comes to medications.
We're talking about what happens after a drug
gets the green light after it's approved and
actually starts being used by patients out in
the real world. Right, because it's not like,
OK, approved, done, safe forever. Right, exactly.
And thankfully, there are these systems in place
to make sure things stay as safe as possible,
even after a drug is out there being prescribed
and taken. And that's what we're going to dig
into today. We're focusing specifically on drug
labels, the info that comes with your meds, risk
management plans, which take a bigger picture
approach, and then something called RAMA -S,
which stands for risk evaluation and mitigation
strategies. These are kind of like specialized
safety protocols for certain medications. You
gave us some really interesting sources to work
with for this deep dive. Yeah, we've got material
that touches on a whole bunch of stuff, like
how drugs actually work in the body. That's your
pharmacokinetics and pharmacodin... all the way
to the legal and regulatory side of things with
excerpts from the Code of Federal Regulations,
the CFR. Yeah, all super important stuff. And
even though we don't have a source that's like
chapter one, labeling, chapter two, risk management,
chapter three, RMS. all these different pieces
really underscore how complex drug behavior can
be and how we need robust systems to catch any
potential problems, even those that maybe don't
show up until a drug is being used more widely.
Absolutely. It's all about creating layers of
safety to protect patients. So let's start with
something we've all seen, the drug label. We
might not give it a ton of thought, but it plays
a huge e -roll in medication safety. One of the
excerpts you shared, the one from the certified
pharmaceutical GMP professional handbook, it
really dives into the nitty gritty of packaging
and labeling regulations. Like, did you know
there were specific guidelines for what needs
to be on those cartons and inserts that come
with your meds? Oh, yeah, for sure. It's all
laid out pretty clearly. And it's not just like,
you know, the brand name and what the drug is
for. We're talking really important stuff, like
how to take it properly, the correct dosage,
when it expires, all that good stuff. And then
there's 21 CFR 211 .132, which I gotta admit,
I didn't know about until reading through these
sources. Yeah, that one's kind of a behind -the
-scenes safety hero, right? It is. It mandates
that most over -the -counter meds have to have
tamper -evident packaging. You know, that little
seal you have to break to get into the bottle.
Seems so basic, but it's a hugey deal. Oh yeah,
that little seal is your first line of defense.
It's a clear visual indicator letting you know,
hey, no one's messed with this medication since
it was packaged. It helps ensure that what you're
taking is exactly what it's supposed to be, nothing's
been tampered with. But the label goes way beyond
just that initial physical protection. It's the
main way that important info about the drug is
communicated, both to the patient and the health
care provider. And what's really fascinating
is that it's not just a one and done kind of
thing. It's a constantly evolving document. You
have to think of the label as an ongoing safety
bulletin for the drug. As more data comes in
from patients actually using it in the real world,
the label can get updated to reflect any new
safety info that comes to light. It's a living
document, really. Wow, I never thought of it
that way like a living document and that makes
so much sense Because you learn so much more
once a drug is actually being used by lots of
people in all sorts of different situations Yeah,
but okay, so the label is the first point of
contact for safety info but it sounds like there's
even more going on behind the scenes to keep
things safe and That's where risk management
plans come in, right? Risk management plans are
taking a wider view, being more proactive. They're
about looking at the entire lifespan of a drug,
trying to anticipate any potential risks that
might pop up, not just what we know right when
it's approved. It's a very systematic way to
approach it. It involves identifying anything
that could potentially go wrong, figuring out
how likely it is to happen and how serious it
could be, and then coming up with strategies
to minimize those risks as much as possible.
So it's like having a plan for what -if scenarios.
Exactly. And thinking back to the source material
you provided, there's a really powerful example
of why this kind of big -picture thinking is
so critical. It's the story of Mipa Ferdil. Oh
yeah, Pazikor. That one stuck with me. If I remember
correctly, it was approved for treating high
blood pressure and chest pain, but then it was
pulled from the market. That was a really big
deal. It was. And the reason it was pulled was
because it turned out to be a very potent inhibitor
of a specific enzyme in the body called CYP3A4.
And that led to some really dangerous interactions
with other drugs that people were taking at the
same time. Yeah, the evaluation of drug candidates
for preclinical development source. goes into
that whole issue. And it's scary because they
kept having to update the label with more and
more warnings, but even that wasn't enough to
keep people safe in the end. No, it wasn't. The
MipiFriddle case is a perfect example of how
Even with all the testing that happens before
a drug is approved, you can still have unforeseen
problems once it's out in the real world. What
seemed relatively safe in clinical trials, where
things are very controlled, ended up causing
serious issues once it was prescribed more widely
and people were taking it along with other medications.
And that's a really important lesson about the
limitations of what we can know before a drug
is actually being used by a large population.
Yeah, it's a sobering reminder. Absolutely. And
to your point, they initially put warnings on
the label about interactions with a handful of
specific drugs. But then reports started coming
in about dangerous, sometimes even fatal interactions
with at least 25 other medications. And a lot
of those were really common drugs like antibiotics
and antihistamines. It basically became impossible
to try to address all of those potential interactions
just through warnings on the label. Wow, that's
really unsettling. And it makes it clear why
understanding how drugs behave in the body is
so important for managing risk. And that's something
that comes up over and over again in the sources
you share. Right, like how drugs are metabolized
by those CYP450 enzymes. There's a whole section
on that. fundamentals of medicinal chemistry,
and then the role of drug transporters. That's
covered in drug interactions. And then on top
of all that, you have individual patient variability,
how people process drugs differently based on
their genetics and other factors. That's all
part of what makes risk management so complex.
So, okay. Risk management is about trying to
anticipate these broader issues and having a
game plan, right? But what about those situations
where a drug has some really significant risks,
even if the potential benefits are still considered
greater than those risks? That's where remes
come in. Exactly. REM -S or risk evaluation and
mitigation strategies are like an extra layer
of safety that the FDA, the Food and Drug Administration
can require for certain drugs. These are situations
where, yes, the drug has been shown to have real
benefits for treating serious conditions, but
there are also some pretty serious potential
downsides that need to be managed very carefully
to make sure the benefits outweigh the risks.
So it's all about weighing the pros and cons
and finding ways to make sure the benefits went
out. Right. You want to make sure people can
access treatments that can really improve their
lives. But you also have to minimize the chances
of them experiencing harm. OK, so REM is provide
a structured approach to doing that. It's not
just about. adding more warnings to the label,
right? Right. REMs go beyond the label and can
include a whole toolbox of different strategies
depending on the specific risks of the drug.
Interesting. What kinds of things are we talking
about? Well, one common component of REMs is
something called a medication guide. It's basically
an easy -to -understand information sheet that's
given directly to the patient, and it explains
the serious risks associated with the medication
in very clear language. It also tells them what
precautions to take and how to use the medication
safely. It's like a patient -friendly companion
to the more technical info on the label. That
makes sense. So it's kind of like a user manual.
Yeah, I like that analogy. Then you also have
REMS components that focus on communicating with
health care providers. Oh, right, because they're
the ones actually prescribing the medications.
Exactly. So there might be letters sent directly
to doctors, articles published in medical journals,
or educational materials provided by the drug
manufacturer. All of these are aimed at making
sure that prescribers are up to date on the latest
safety information and that they know how to
counsel their patients appropriately. It sounds
like it's really about making sure everyone is
on the same page. Exactly, and then in some cases,
REMS can include things like restricted distribution
systems. This is when a drug is only available
through certain certified pharmacies or only
to patients who meet certain specific criteria
and are enrolled in a special registry. Wow,
so it can get... Pretty intense. Yeah, for drugs
with really serious risks, you need more than
just information. You need to control access.
And then sometimes there are also monitoring
requirements. This could mean that patients have
to have regular blood tests or other types of
checkups while they're taking the medication
to make sure everything is OK. All these different
components work together to support safe use
of the medication after it's been approved. So
it's really about tailoring the safety measures
to the specific risks of each individual drug.
Precisely. It's about being targeted and strategic,
not just a one -size -fits -all approach. It
sounds like there's a big emphasis on getting
the right information to the right people at
the right time, both for patients and for health
care professionals. So how does that actually
work? How do you make sure the message about
risks is communicated effectively? Well, like
we were talking about before, the drug label
is the foundation. It's the first place a doctor
or pharmacist is going to look for information
about dosing, contraindications, which means
when the drug shouldn't be used, and any potential
side effects. But when a REM is in place, the
communication efforts are kicked up a notch.
You've got those medication guides that we were
talking about, which are designed to clearly
and directly inform the patient about the risks
involved. And then there are a bunch of ways
to get the info to healthcare providers. Letters,
medical journal articles, educational materials.
It's all about keeping them in the loop about
the latest safety findings and making sure they
have what they need to educate their patients.
Oh, absolutely. Patients and doctors have different
needs and different levels of understanding when
it comes to medical information. Okay, so communicating
the risks upfront is essential, but then there's
the whole process of monitoring patient safety
once a drug is out in the world and being used
by a much larger population. That must be a huge
E undertaking. It definitely is. Post -approval
safety surveillance is an ongoing, continuous
process. It involves collecting and analyzing
reports of any adverse events that occur. Adverse
events meaning? Adverse events were basically
any unexpected or harmful reactions that someone
might experience while taking a medication. So
it's like keeping track of any bad side effects
that crop up. Exactly. And those reports can
come from patients, from doctors, even from the
drug manufacturer themselves. And the FDA...
They play a critical role here, as you can see
from the CFR excerpts. They're constantly monitoring
all of this data that's coming in, looking for
any red flags or trends that maybe weren't obvious
during the clinical trials. Remember, clinical
trials only involve a limited number of people.
But once a drug is approved, it's being used
by thousands, even millions of people. So it's
really important to keep tabs on what's happening.
And that monitoring can lead to changes in how
a drug is used or even whether it's available
at all, right? It can, and it does. Based on
the data they're getting from post -approval
surveillance, the FDA might decide that a drug
label needs to be updated to include new warnings,
or they might implement a new REMS, or in really
extreme cases, if the risks are just too great,
they might even pull a drug from the market altogether.
That's what happened with Mibifridyl, which we
were talking about earlier. So basically, the
FDA is constantly evaluating new information
and making adjustments to keep people as safe
as possible. That's exactly right. And that's
one of the main ways that drug safety is managed
in the long term. It's a never -ending process
of learning and adapting. One of the sources
you gave me, the one on developing solid oral
dosage forms, mentioned something called post
-approval changes and supplements to approved
applications. Oh, yeah. Those are the formal
mechanisms for making changes to how a drug is
manufactured, labeled, or even used based on
the data that comes in after it's been approved.
It could be something as simple as revising the
wording on the label, or it could be a more significant
change to the manufacturing process. It really
highlights how much is happening behind the scenes
to keep medication safe. It's not just a set
it and forget it kind of thing. Not at all. It's
a very dynamic process, constantly evolving,
and this is where the science really comes into
play. All the stuff we were talking about earlier,
pharmacology, toxicology, pharmacokinetics, pharmacodynamics,
all of that knowledge helps us understand how
a drug works in the body, how it interacts with
other substances, and what the potential risks
might be. Right, so it's not just about regulations
for the sake of having regulations, it's about
using scientific knowledge to make informed decisions
about safety. Exactly. Understanding a drug's
absorption, distribution, metabolism, and excretion,
that's what ADME stands for, as well as its specific
effects on the body, those are all essential
pieces of the puzzle. And the regulatory frameworks,
like the CFR, they provide the structure and
the specific requirements for how we translate
that scientific knowledge into concrete actions
to make sure drugs are used as safely as possible.
It's a really cool partnership between science
and regulation, all working together to protect
patients. So for everyone listening, the key
takeaway here is that ensuring drug safety doesn't
stop once a medication is approved. It's an ongoing
process. Drug labeling provides vital information.
Risk management plans take a broader proactive
approach to try to anticipate and prevent potential
problems. And REMs offer targeted strategies
for managing the risks associated with specific
medications. All these efforts are interconnected
and work together to protect public health. And
I think this deep dive really shows how complex
and interconnected all of this is. It's a testament
to the commitment of so many people, scientists,
regulators, health care providers, to constantly
learning and adapting to make sure medications
are used as safely and effectively as possible.
It's really impressive. And it makes you think.
What kind of information or resources related
to medication risks would you find most helpful?
Whether you're a patient, a healthcare provider,
or just someone who wants to be more informed
about this stuff. It's a conversation that needs
to keep happening. I agree. The more we talk
about these issues, the more awareness we raise,
and the better equipped everyone will be to make
informed decisions about their health. Well said.
Thanks for joining us today. This was a really
enlightening conversation. My pleasure. Thanks
for having me.